(Q37944437)

25 August 2017

title

Urothelial carcinoma of the bladder: definition, treatment and future efforts (English)

1 reference

25 August 2017

Sandip M Prasad

1

1 reference

25 August 2017

G Joel Decastro

series ordinal

2

1 reference

25 August 2017

Gary D Steinberg

series ordinal

3

1 reference

25 August 2017

Medscape

series ordinal

4

1 reference

25 August 2017

language of work or name

English

0 references

publication date

11 October 2011

1 reference

25 August 2017

published in

Nature Reviews Urology

1 reference

25 August 2017

volume

8

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

631-642

1 reference

25 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Gender differences in stage distribution of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Gender and geographic influence on the racial disparity in bladder cancer mortality in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival: findings from the National Longitudinal Mortality Study, 1979-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Conservative management of low risk superficial bladder tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Defining optimal therapy for muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Factors affecting recurrence and progression in superficial bladder tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Multivariate analysis of the prognostic factors of primary superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Nomograms for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Are nomograms needed in the management of bladder cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Non-muscle-invasive bladder cancer: the role of radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

T1G3 bladder cancer--indications for early cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Lymphovascular invasion as a prognostic tool for advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The impact of variant histology on the outcome of bladder cancer treated with curative intent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

A case of relapsing secondary bladder adenocarcinoma after right colonic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Case of carcinosarcoma of urinary bladder obtained a pathologically complete response by neoadjuvant chemoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Small cell carcinoma of the urinary bladder. The Mayo Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Urothelial tumorigenesis: a tale of divergent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Genetic alterations in urothelial bladder carcinoma: an updated review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Multi–Detector Row CT Urography in the Evaluation of Hematuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

New imaging modalities in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Urine cytology. It is still the gold standard for screening?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Urinary markers in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The value of a second transurethral resection in evaluating patients with bladder tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Treatment options for BCG failures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Combination of BCG and interferon intravesical immunotherapy: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Immunotherapeutic strategies for high-risk bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Intravesical treatments of bladder cancer: review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The role of lymphadenectomy in high-grade invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The Will Rogers phenomenon in urological oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The role of taxanes in the management of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Novel strategies for treating relapsed/refractory urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Vinflunine in the treatment of advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Gene discovery in bladder cancer progression using cDNA microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Molecular biomarkers in urothelial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Genetic and epigenetic aspects of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Effective therapy for metastatic renal cancer, whither to now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

BCAN Think Tank session 3: Prevention of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Selenium and bladder cancer risk: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The health economics of bladder cancer: a comprehensive review of the published literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Sex and racial differences in bladder cancer presentation and mortality in the US

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Sex and race in bladder cancer: what we have learned and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Delaying Radical Cystectomy for Muscle Invasive Bladder Cancer Results in Worse Pathological Stage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Superficial bladder cancer: the primacy of grade in the development of invasive disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

High-grade hyperinvasive sarcomatoid urothelial bladder carcinoma demonstrating complete response to bladder-preserving chemoradiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect the rate of upstaging in cT1 bladder cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The value of a second transurethral resection in evaluating patients with bladder tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The value of a second transurethral resection for T1 bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Impact of a second transurethral resection on the staging of T1 bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Early vs delayed radical cystectomy for 'high-risk' carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Outcome after radical cystectomy with limited or extended pelvic lymph node dissection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Advanced bladder cancer: so many drugs, so little progress : what's wrong with this picture?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Can patient selection for bladder preservation be based on response to chemotherapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Chemoprevention of bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.144

Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710)

31 March 2020

1 reference

12 December 2020

Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).

1 reference

12 December 2020

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

1 reference

12 December 2020

Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.

1 reference

12 December 2020

The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer

1 reference

12 December 2020

Hydronephrosis as a prognostic indicator in bladder cancer patients

1 reference

12 December 2020

Neural network analysis of clinicopathological and molecular markers in bladder cancer.

1 reference

12 December 2020

Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer

1 reference

12 December 2020

An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma

1 reference

12 December 2020

Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2011.144

1 reference

release_3l3n7kw3xvgpreo7ys4p6h3v7m

25 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3l3n7kw3xvgpreo7ys4p6h3v7m

24 November 2022

mapped directly with Wikidata item

1 reference